Crinetics Pharmaceuticals, Inc. 4

Chief Commercial Officer Isabel Kalofonos had all of her Crinetics Pharmaceuticals, Inc. common shares, RSUs, and in-the-money stock options canceled and cashed out in connection with the September 1, 2026 cash merger at $85 per share.

On September 1, 2026, coincident with the closing of Crinetics Pharmaceuticals, Inc.’s cash merger with Vertex Pharmaceuticals at $85.00 per share, Chief Commercial Officer Isabel Kalofonos had all of her equity in Crinetics cashed out or canceled in accordance with the merger agreement. This included 1,669 common shares (note that her holdings included 835 shares acquired via the employee stock purchase plan) converted into cash at $85 per share (approximately $141,865), and 34,000 restricted stock units that fully vested immediately prior to closing and were then canceled for cash at $85 per unit (about $2.89 million). In addition, in-the-money stock options covering 97,500 shares with a weighted average intrinsic value of $40.59 per share (implying an exercise price of roughly $44.41 versus the $85 cash price, for an estimated cash-out value of about $3.96 million) and a further 55,000 in-the-money options with intrinsic value of $43.79 per share (implied exercise price about $41.21, for roughly $2.41 million in value) were canceled and converted into cash, while any options with exercise prices at or above $85 were canceled for no consideration. Following these merger-related cash-out and cancellation events, Kalofonos reported no remaining ownership of Crinetics securities, as the company became a wholly owned subsidiary of Vertex.

Filing Facts

CIK

1658247

Ticker

CRNX

Form

4

Source Type

fda

Accession

0001628280-26-059885

Alert Tier

6